It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector.
Atai, MindMed, Enveric, Mydecine and Filament Health all released their numbers for 2021, with positions varying between “very well-capitalized” to “almost out of cash.” As we reviewed in our analysis piece for the week, this period marks a turning point in the industry in which the sector is starting to consolidate amongst its best-prepared players. We foresee a wave of companies lacking the cash to complete their business plans before the end of the year.
